Policy
Steve Ubl's announcement that he will step down as president and CEO of PhRMA signals that the political architecture the pharmaceutical industry built over the past decade is under unprecedented stress.
Pharmaceuticals
Novo Nordisk launched Wegovy HD at $399 per month, undercutting Lilly's Zepbound by $50. The move signals a new phase in the GLP-1 market where pricing strategy and clinical differentiation are becoming inseparable.
Biotechnology
Gilead Sciences is acquiring German ADC biotech Tubulis for up to $5 billion, its third major oncology deal in 2026. The transaction reveals why antibody-drug conjugates have become the most fiercely contested technology platform in cancer drug development.
Biotechnology
Neurocrine Biosciences is paying $2.9 billion for Soleno Therapeutics and its first-in-class hyperphagia drug Vykat XR. The deal reveals how rare disease M&A works when the science finally catches up to a condition that has been waiting decades for a targeted therapy.
Biotechnology
Biogen's $5.6 billion acquisition of Apellis Pharmaceuticals signals a strategic shift from neuroscience to immunology and rare disease, revealing new patterns in biotech M&A and corporate reinvention.
Policy
Trump's executive order imposing 100% tariffs on imported branded pharmaceuticals marks a structural turning point for the industry. Here is what the order actually says, who it protects, and what it risks.
Biotechnology
Eli Lilly's $6.3 billion acquisition of Centessa Pharmaceuticals signals a major pharmaceutical bet on orexin receptor biology and sleep medicine—revealing where the industry's capital is flowing beyond the GLP-1 wave.
Pharmaceuticals
Merck's enlicitide data from the CORALreef AddOn trial demonstrates that an oral PCSK9 inhibitor can achieve injectable-like LDL reductions of 64.6%, potentially transforming cholesterol management by eliminating the injection barrier that has limited patient access for over a decade.
Biotechnology
Eli Lilly's $2.75 billion commitment to Insilico Medicine represents the most significant commercial validation of AI drug discovery to date—a bet on proven capability, not theoretical potential.
Thoughts, stories and ideas.
Bristol Myers Squibb's SCOUT-HCM trial demonstrates that Camzyos (mavacamten) is effective and safe in adolescents with obstructive hypertrophic cardiomyopathy, marking the first Phase 3 trial of a cardiac myosin inhibitor in a pediatric population and reshaping treatment options for young patients.
The FDA's approval of Denali's Avlayah marks a breakthrough in blood-brain barrier delivery and signals the agency's continued commitment to rare disease innovation amid recent regulatory turbulence.
The Trump administration is waging one of its most aggressive campaigns against healthcare fraud in years, and wound care is squarely in the crosshairs. In February 2026, the Centers for Medicare & Medicaid Services (CMS) imposed a nationwide six-month moratorium on new Medicare enrollment for certain medical supply companies, citing
Ionis Pharmaceuticals cuts Tryngolza's price by 93%, from $595,000 to $40,000 annually, signaling a strategic shift in rare disease drug pricing ahead of a broader indication approval.
The FDA's approval of nivolumab plus chemotherapy for previously untreated Stage III and IV classical Hodgkin lymphoma on March 20, 2026 marks the formal arrival of immunotherapy at the front line of one of oncology's most treatable cancers.
There is a particular kind of corporate transaction that tells you more about where an industry is heading than any analyst forecast. Abbott's completion of its $21 billion acquisition of Exact Sciences on March 23, 2026 is one of those transactions. It is not simply a large deal
Eli Lilly's Phase 3 retatrutide data reveals a triple-acting metabolic drug that may push weight loss efficacy beyond tirzepatide, with patients losing up to 15% of body weight over 40 weeks—and the trajectory still heading downward.
The FDA approved IMCIVREE (setmelanotide) as the first therapy for acquired hypothalamic obesity on March 19, 2026. Here is what the TRANSCEND trial data mean for patients, the MC4R pathway platform, and the rare disease market.
For the roughly 125 million people worldwide living with psoriasis, the treatment conversation has long followed a familiar and frustrating arc. Start with topical creams. Cycle through them. Graduate, eventually, to an injectable biologic that requires a needle, a refrigerator, and a willingness to self-administer a shot every few weeks
Pfizer's Phase 2 FOURLIGHT-1 data on atirmociclib show a 40% reduction in disease progression risk in CDK4/6 inhibitor-resistant breast cancer, positioning the selective CDK4 inhibitor as a potential successor to Ibrance ahead of its 2027 patent expiry.
Structure Therapeutics' aleniglipron showed 15% weight loss in Phase 2 trials, delivering injectable-like efficacy in pill form and reshaping the competitive landscape for oral GLP-1 obesity drugs.
Sana Biotechnology's 14-month follow-up data shows transplanted insulin-producing cells surviving and functioning without immunosuppression—a potential breakthrough in type 1 diabetes treatment.
